Phase I clinical trial to assess safety and efficacy of Oraxol, a novel oral paclitaxel chemotherapy agent, in patients with previously treated metastatic breast cancer
Abstract Oraxol, a novel oral paclitaxel chemotherapy agent, has emerged as a potential alternative for treating metastatic breast cancer (MBC). However, its safety and efficacy remain uncertain due to insufficient evidence supporting it. This open‐label, single‐arm, phase I trial was designed to as...
Saved in:
| Main Authors: | Yunfang Yu, Ying Wang, Luhui Mao, Suiwen Ye, Xiuping Lai, Junyi Chen, Yiwen Zhang, Jieqiong Liu, Junyan Wu, Tao Qin, Herui Yao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.70097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01) -
A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancerResearch in context
by: Qiang Wen, et al.
Published: (2025-07-01) -
The efficacy of regorafenib monotherapy as the third-and later-line treatment for metastatic colorectal cancer: a retrospective study
by: An Tianqi, et al.
Published: (2022-08-01) -
Response of Capecitabine and Oxaliplatin Chemotherapy in Metastatic Colorectal Carcinoma
by: Asma Abdul Rashid, et al.
Published: (2025-01-01) -
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis
by: Yating Dian, et al.
Published: (2024-12-01)